Cargando...
Bifeprunox versus placebo for schizophrenia
BACKGROUND: Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long‐term symptoms of schizop...
Gardado en:
| Publicado en: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2016
|
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6457956/ https://ncbi.nlm.nih.gov/pubmed/27732740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012029.pub2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|